Синдром підвищеної кишкової проникності: акцент на мікробіоту
DOI:
https://doi.org/10.30978/MG-2018-3-85Ключові слова:
підвищена кишкова проникність, мікробіота, пробіотики, «Лінекс®»Анотація
Наведено дані літератури щодо синдрому підвищеної кишкової проникності, ролі порушень кишкової мікробіоти в розвитку підвищеної кишкової проникності та впливу на розвиток захворювань кишечника, печінки, серцево-судинної і нервової системи, метаболічних порушень, особливостей дієтичної корекції та застосування пробіотиків.
Посилання
Айтбаев КА, Мураталиев ТМ. Манипуляции с кишечной микрофлорой как новая парадигма для диагностики, терапии и профилактики кардиоваскулярных заболеваний (Обзор литературы). Вестн Кыргызско-Российского Славянского Университета. 2015;15(7):10.
Барановский АЮ, Симаненков ВИ. Достижения и перспективы изучения функциональных и воспалительных заболеваний кишечника в СПбМАПО. Вестн Сев. Запад. гос. мед. ун-та имени И. И. Мечникова. 2010; № 2 (2):121—34.
Бондаренко ВМ, Рябиченко ЕВ. Роль дисфункции кишечного барьера в поддержании хронического воспалительного процесса различной локализации. Микробиол, эпидемиол и иммунобиол. 2010;1:92-100.
Борщев ЮЮ, Ермоленко ЕИ. Метаболический синдром и микроэкология кишечника. Трансляционная медицина. 2014;1:19—28.
Каштанова ДА, Ткачева ОН, Бойцов СА. Микробиота кишечника и факторы кардиоваскулярного риска. Ч. 1. Микробиота кишечника, возраст и пол. Кардиоваскулярная терапия и профилактика. 2015;4:92—95.
Каштанова ДА, Ткачева ОН, Бойцов СА. Микробиота кишечника и факторы кардиоваскулярного риска. Ч. 2. Микробиология кишечника и ожирение. Кардиоваскулярная терапия и профилактика. 2015;5:83—86.
Кучумова СЮ, Полуэктова ЕА, Шептулин АА, Ивашкин ВТ. Физиологическое значение кишечной микрофлоры. Рос журн гастроэнтерол, гепатол, колопроктол. 2011;21(5):17—27.
Петухов ВА, Стернина ЛА, Травкин АЕ. Нарушения функций печени и дисбиоз при липидном дистресс-синдроме Савельева: современный взгляд на проблему. Consilium medicum. 2004;6(6):406—409.
Полуэктова ЕА, Ляшенко ОС, Королев АВ. и др. Механизмы, обеспечивающие взаимодействие бактериальных клеток с организмом хозяина, и их нарушение у пациентов с воспалительными заболеваниями кишечника. Рос журн гастроэнтерол, гепатол, колопроктол. 2014;24(5):42—53.
Редакционная статья. Микробиота кишечника и атеросклероз. Клиническая фармакология и терапия. 2013;22(3):5—11.
Ткач СМ, Тимошенко АС, Дорофеева АА. Роль кишкової мікробіоти у розвитку ожиріння та інсулінорезистентності. Клінічна ендокринологія та ендокринна хірургія. 2016;1 (53).
Ткачева ОН, Каштанова ДА, Бойцов СА. Микробиота кишечника и факторы кардиоваскулярного риска. Ч. 3. Липидный профиль, углеводный обмен и микробиота кишечника. Кардиоваскулярная терапия и профилактика. 2015;14(6):83—86.
Ткачев АВ, Мкртчян ЛС, Никитина КЕ. и др. Воспалительные заболевания кишечника: на перекрестке проблем. Практическая медицина. 2012;N 3 (12).
Ушакова ЕА, Зырянов СК. Место препаратов, влияющих на микробиоту кишечника, в современной медицине. Consilium medicum Приложение Педиатрия. 2017;2. C. 3-7.
Чихачева Е, Селиверстов П, Тетерина Л. и др. Микробиоценоз кишечника при хронических заболеваниях печени: диагностика и лечение. Врач. 2011;7:18—21.
Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:691—701.
Aller R, De Luis DA, Izaola O et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011;15:1090 — 1095.
Amar J, Burcelin R, Ruidavets JB et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr. 2008;87:1219-1223.
Amar J, Serino M, Lange C et al., D. E.S. I.R. Study Group. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia. 2011;54:3055-3061.
Angelakis E, Armougom F, Million M, Raoult D. The relationship between gut microbiota and weight gain in humans. Future Microbiol. 2012;N 7 (1):91-109.
Anitha M, Chandrasekharan B, Salgado JR et al. Glial-derived neurotrophic factor modulates entericneuronal survival and proliferation through neuropeptideY. Gastroenterol. 2006;131:1164-1178.
Ardissone AN, de la Cruz DM, Davis-Richardson AG et al. Meconium microbiome analysis identifies bacteria correlated with premature birth. PLoS One. 2014;9. e90784.
Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol. 2013;29:79-84.
Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol. 2008;8:411-420.
Arumugam M, Raes J, Pelletier E et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174 — 180.
Azad MB, Konya T, Maughan H et al. Gut microbiota of healthy Canadian infants: profi les by mode of delivery and infant diet at 4 months. CMAJ. 2013;185:385-394.
Bailey LC et al. Association of antibiotics in infancy with early childhood obesity. JAMA. Pediatr. 2014;168:1063-1069.
Balamurugan R, George G, Kabeerdoss J et al. Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children. Br J Nutr. 2010;103:335-338.
Braegger C et al. Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition. J Pediatr Gastroenterol Nutr. 2011;52:238-250.
Cani PD et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761-1772.
Cani PD. Metabolism in 2013: The gut microbiota manages host metabolism. Nature Reviews Endocrinology. 2014;10:74-76.
Cani PD, Delzenne NM. Gut microflora as a target for energy and metabolic homeostasis. Curr Opin Clin Nutr Metab Care. 2007;10:729-734.
Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 2009;15:1546-1558.
Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade i.nflammation and type 2 diabetes associated with obesity. Gut Microbes. 2012;N 3.
Cannon JP, Lee TA, Bolanos JT, Danziger LH. Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis. 2005;24:31-40.
Cappellano G, Carecchio M, Fleetwood T et al. Immunity and inflammation in neurodegenerative diseases. Am J Neurodegener Dis. 2013;N 2:89-107.
Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol Hepatol. 2015;28:203-209.
Cesaro C, Tiso A, Del Prete A et al. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis. 2011;43:431—438.
Clarke G, Grenham S, Scully P et al. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry. 2013;18:666-673.
D’ Souza S, Levy E, Mack D et al. Dietary patterns and risk for Crohn’s disease in children. Inflam Bowel Dis. 2008;14:367-373.
Delzenne NM, Neyrinck AM, Backhed F, Cani PD. Targeting gut microbiota in obesity. P. effects of prebiotics and probiotics. Nat Rev Endocrinology. 2011;7:639-646.
Delzenne NM, Neyrinck AM, Cani PD. Gut microbiota and metabolic disorders: How prebiotic can work?. Br J Nutr. ition. 2013;109, suppl 2. P. S81–S85.
Desbonnet L, Garrett L, Clarke G et al. Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscie. 2010;170:1179-1188.
Desbonnet L, Garrett L, Clarke G et al. The probiotic Bifidobacteria infantis: an assessment of potential antidepressant properties in the rat. J Psychiatr Res. 2009;4:164-174 doi: 10.1016/j.jpsychires.2008.03.009
Di Baise JK, Zhang H, Crowell MD et al. Gut microbiota and its relationship with obesity. Mayo Clin Proc. 2008;83(4):460-469.
Dickerson FB, Schroeder JR, Yolken RH, Crandall KA. Composition, taxonomy and functional diversity of the oropharynx microbiome in individuals with schizophrenia and controls. Peer J. 2015;3. e1140.
Dinicolantonio JJ, Lavie CJ, Fares H et al. L-carnitine in the secondary prevention of cardiovascular disease: Systematic review and meta-analysis. Mayo Clin Proc. 2013
Doege K et al. Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood — a meta-analysis. Br J Nutr. 2012;107:1-6.
Dominguez-Bello MG, Costello EK, Contreras M et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U SA. 2010;107:11971-11975.
Everard A, Cani PD. Diabetes, obesity and gut microbiota. Best practice research. Clin Gastroenterol. 2013;27:73-83.
Finegold SM, Dowd SE, Gontcharova V et al. Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe. 2010;16:444-453.
Finegold SM, Molitoris D, Song Y et al. Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis. 2002;35. P. S6–S16.
Flanagan P, Campbell BJ, Rhodes JM. Bacteria in the pathogenesis of inflammatory bowel disease. Biochem Soc Trans. 2011;39:1067-1072.
Forsyth CB, Shannon KM, Kordower JH et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’ s disease. PLoS One. 2011;6. e28032.
Foster JA, McVey Neufeld K. A. Gut–brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 2013;36:305-312.
Friedland RP. Mechanisms of molecular mimicry involving the microbiota in neurodegeneration. J Alzheimers Dis. 2015;45:349-362.
Garrett WS, Gordon JI, Glimcher LH. Homeostasis and inflammation in the intestine. Cell. 2010;140:859-870.
Gentschew L, Ferguson LR. Role of nutrition and microbiota in susceptibility to inflammatory bowel diseases. Mol Nutr Food Res. 2012;56:524-553.
Gómez-Hurtado I, Such J, Sanz Y, Francés R. Gut microbiota-related complications in cirrhosis. World J Gastroenterol. 2014;20 (42):15624-15631.
Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Ann Rev Immunol. 2011;29:415-445.
Haller D. Nutrigenomics and IBD: the intestinal microbiota at the cross-road between inflammation and metabolism. J Clin Gastroenterol. 2010;44, suppl 1. P. S6–S9.
Hammer HF. Gut microbiota and inflammatory bowel disease. Dig Dis. 2011;29:550-553.
Harach T, Marungruang N, Dutilleul N et al. Reduction of Alzheimer’ s disease beta-amyloid pathology in the absence of gut microbiota 2015
Hasegawa S, Goto S, Tsuji H et al. Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson’s disease. PLoS One — 2015;10. e0142164.
Hill JM, Lukiw WJ. Microbial-generated amyloids and Alzheimer’ s disease (AD). Front Aging Neurosci. 2015;7:9.
Hoban AE, Stilling RM, Ryan FJ et al. Regulation of prefrontal cortex myelination by the microbiota. Transl Psychiatry. 2016;6. e774.
Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336:1268-1273.
Horta BL, de Mola CL, Victora CG. Long-term consequences of breastfeeding on cholesterol, obesity, systolic blood pressure, and type-2 diabetes: systematic review and meta-analysis. Acta Paediatr Suppl. 2015;104:30-37.
Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486:207-214.
Hungin AP, Mulligan C, Pot B. Systematic review: Probiotics in the management of lower gastrointestinal symptoms in clinical practice — an evidence-based international guide. Aliment Pharmacol Ther. 2013;N 38:864—886.
Ishikawa H, Akedo I, Umesaki Y et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003;22:56-63.
Keohane J et al. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation?. Am J Gastroenterol. 2010;105:1789-1794.
Kerckhoffs AP, Linde JJ, Akkermans LM et al. Serotonin transporter transcript levels and serotonin contentare increased in small intestine of irritable bowel syndrome patients. Neurogastroenterol Motil. 2008;20:900-907.
Keshavarzian A, Green SJ, Engen PA et al. Colonic bacterial composition in Parkinson’ s disease. Mov Disord. 2015;30:1351-1360.
Kim S. O. et al. Effects of probiotics for the treatment of atopic dermatitis: a meta-analysis of randomized controlled trials. Ann Allergy Asthma Immunol. 2014;113:217-226.
Koenig JE, Spor A, Scalfone N et al. Succession of microbial consortia in the developing infant gut microbiome. PNAS. 2011;108:4578—4585.
Koeth RA, Wang Z, Levison BS et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013.
Kondo S, Xiao J, Saton T et al. Antiobesity effects of Bifidobacterium breve Strain B-3 supplementation in a mouse model with high-fat diet-induced obesity. Biosci Biotechnol Biochem. 2010;74:1656-1661.
Loscalzo J. Gut microbiota, the genome, and diet in atherogenesis. N Engl J Med. 2013;368 (17):1647-1649.
Macfarlane GT, Macfarlane S. Bacteria, colonic fermentation, and gastrointestinal health. J AOAC Int. 2012;95:50-60.
Major G, Spiller R. Irritable bowel syndrome, inflammatory bowel disease and the microbiome. Curr Opin Endocrinol Diabetes Obes. 2014;21:15-21.
Mayer EA, Knight R, Mazmanian SK et al. Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci. 2014;34:15490-15496.
McAuley JL, Linden SK, Png CW et al. MUC1 cell surface mucin is a critical element of the mucosal barrier to infection. J Clin Invest. 2007;117:2313-2324.
Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterol. 2012;142:46-54.
Nieuwdorp M, Gilijamse Pim W, Pai Nikhil, Kaplan Lee M. Role of the microbiome in energy regulation and metabolism. Gastroenterol. 2014;146:1525-1533.
O’ Hara AM, Shanahan F. Gut microbiota: mining for therapeutic potential. Clin Gastroenterol Hepatol. 2007;5:274-284.
Pedersen N, Kofod Vinding K, Vegh Z et al. Gut Microbiota in IBD patients with IBS before and after 6 weeks of low FODMAP diet. Abstract Nr: P474 ECCO. 2014.
Petschow B, Dore J, Hibberd P et al. Probiotics, prebiotics, and the host microbiome.: the science of translation. Annals of the New York Academy of Sciences. 2013;22:12303.
Porras M, Martín MT, Yang PC et al. Correlation between cyclical epithelial barrier dysfunction and bacterial translocation in the relapses of intestinal inflammation. Inflam Bowel Dis. 2006;12(9):843-852.
Qin J, Li R, Raes J et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59-65.
Reuter G. The Lactobacillus and Bifidobacterium microflora of the human inte¬stine: composition and succession. Curr Issues Intest Microbiol. 2001;2:43-53.
Roberts CL, Keita AV, Duncan SH et al. Translocation of Crohn’s disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut. 2010;59:1331-1339.
Ruemmele FM, Veres G, Kolho KL et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179-1207.
Sa’ad Y. S., Söderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflammatory Bowel Diseases. 2011;17(1):362-381.
Saffrey MJ. Ageing of the enteric nervous system. Mech Ageing Dev. 2004;125:899-906.
Sartor RB. Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterol. 2010;139:1816-1819.
Scheperjans F, Aho V, Pereira PA.B. et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord. 2015;30:350-358.
Sherman PM, Ossa JC, Johnson-Henry K. Unraveling mechanisms of action of probiotics. Nutr Clin Pract. 2009;N 24:10—14.
Sjögren YM, Jenmalm MC, Böttcher MF et al. Altered early infant gut microbiota in children developing allergy up to 5 years of age. Clin Exp Allergy. 2009;39:518-526.
Smythies LE, Smythies JR. Microbiota, the immune system, black moods and the brain-melancholia updated. Front Hum Neurosci. 2014;8:720. doi: 10.3389/fnhum.2014.00720
Tang WH, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest. 2014;124 (10):4204-4211.
Tang WH.W., Wang Z, Levison BS et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368 (17):1575-1584.
Tilg H. Diet and intestinal immunity. N Engl J Med. 2012;366:181-183.
Tilg H. Obesity, metabolic syndrome, and microbiota: multiple interactions. J Clin Gastroentero. 2010;44 (suppl 1). P. S16–S18.
Wang Z, Klipfell E, Bennett BJ et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472 (7341):57-63.
Wehkamp J, Antoni L, Ostaff M, Stange EF. The intestinal barrier in implications for future therapeutic intervention. Falk Foundation. 2013:36-37.
